Premium
131 I‐labeled antibodies to human fibrinogen. Diagnostic studies and therapeutic trials
Author(s) -
Spar Irving L.,
Bale William F.,
Marrack David,
Dewey William C.,
McCardle Robert J.,
Harper Paul V.
Publication year - 1967
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(1967)20:5<865::aid-cncr2820200546>3.0.co;2-5
Subject(s) - medicine , fibrinogen , antibody , melanoma , clinical trial , pathology , cancer , immunology , cancer research
Homologous 131 I fibrinogen and its purified antibody will concentrate in a major portion of the neoplasms of the dogs and humans into which they are injected, according to new data. This report gives the scintillation scanning results obtained after iv administration of 131 I‐labeled and purified antihuman fibrinogen to 172 consecutive patients with various types of neoplasms. In 75% (129/172) of the cases the tumor, in various sites, was unequivocally located. These included mammary carcinomas (12/17), malignant melanoma (16/26), bronchogenic carcinoma (27/34), osteogenic sarcomas (9/9), hypernephromas (6/6), and primary tumors of the brain (10/18). The 131 I deposition in tumor relative to normal tissue and blood was so great that in 12 terminal patients therapeutic trials were initiated using 100 to 160 me of the labeled antibody preparation. In some of these attempts, there was substantial remission of clinical symptoms. The usefulness of this technique for specific radiation therapy of tumors will be greatly improved when methods are developed for increasing 131 I concentration in the peoplasm. Several approaches, including fever, endotoxin, pretreatment with fibrinolytic agents and post‐treatment with antifibrinolytic agents, are under intensive investigation in experiments and offer great promise.